Synapse

← Blood Cancer Discovery

Papers in Blood Cancer Discovery

Page 9 · newest first

  1. Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple MyelomaBlood Cancer Discovery · 2021
  2. Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed TherapyBlood Cancer Discovery · 2021
  3. ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow MicroenvironmentBlood Cancer Discovery · 2021
  4. SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid LeukemiaBlood Cancer Discovery · 2021
  5. Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical Determinants in Patients with MDSBlood Cancer Discovery · 2021
  6. Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic MalignanciesBlood Cancer Discovery · 2021
  7. Large-scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood CancersBlood Cancer Discovery · 2021
  8. Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step toward Achieving Equity in HealthcareBlood Cancer Discovery · 2021
  9. Ectopic Humanized Mesenchymal Niche in Mice Enables Robust Engraftment of Myelodysplastic Stem CellsBlood Cancer Discovery · 2020
  10. TFEB Links MYC Signaling to Epigenetic Control of Myeloid Differentiation and Acute Myeloid LeukemiaBlood Cancer Discovery · 2020
  11. A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient Cells in Myeloid NeoplasmsBlood Cancer Discovery · 2020
  12. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 InhibitorsBlood Cancer Discovery · 2020
  13. Understanding FLT3 Inhibitor Resistance to Rationalize Combinatorial AML TherapiesBlood Cancer Discovery · 2020
  14. A Novel Function of Sphingolipid Signaling via S1PR3 in Hematopoietic and Leukemic Stem CellsBlood Cancer Discovery · 2020
  15. Sphingosine-1-Phosphate Receptor 3 Potentiates Inflammatory Programs in Normal and Leukemia Stem Cells to Promote DifferentiationBlood Cancer Discovery · 2020
  16. T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted TherapiesBlood Cancer Discovery · 2020
  17. A Tumor Suppressor Enhancer of PTEN in T-cell Development and LeukemiaBlood Cancer Discovery · 2020
  18. An Autochthonous Mouse Model of Myd88 - and BCL2 -Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular VulnerabilitiesBlood Cancer Discovery · 2020
  19. Viral Immunity and Vaccines in Hematologic Malignancies: Implications for COVID-19Blood Cancer Discovery · 2020
  20. Don't Compromise Myeloma Care Due to COVID-19 Pandemic!Blood Cancer Discovery · 2020
  21. Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic LeukemiaBlood Cancer Discovery · 2020
  22. Revealing the Impact of Structural Variants in Multiple MyelomaBlood Cancer Discovery · 2020
  23. PRPS-ST: A Protocol-Agnostic Self-training Method for Gene Expression–Based Classification of Blood CancersBlood Cancer Discovery · 2020
  24. Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid LeukemiaBlood Cancer Discovery · 2020
  25. COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic CentersBlood Cancer Discovery · 2020
  26. Combinatorial ETS1-Dependent Control of Oncogenic NOTCH1 Enhancers in T-cell LeukemiaBlood Cancer Discovery · 2020
  27. BCOR Binding to MLL-AF9 Is Essential for Leukemia via Altered EYA1, SIX, and MYC ActivityBlood Cancer Discovery · 2020
  28. Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple MyelomaBlood Cancer Discovery · 2020
  29. Epitranscriptomics in Hematopoiesis and Hematologic MalignanciesBlood Cancer Discovery · 2020
  30. Genomic Characterization of HIV-Associated Plasmablastic Lymphoma Identifies Pervasive Mutations in the JAK–STAT PathwayBlood Cancer Discovery · 2020
  31. Mutational Landscape and Patterns of Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic LeukemiaBlood Cancer Discovery · 2020
  32. Cytotoxic Therapy–Induced Effects on Both Hematopoietic and Marrow Stromal Cells Promotes Therapy-Related Myeloid NeoplasmsBlood Cancer Discovery · 2020
  33. MEF2D Fusions Drive Oncogenic Pre-BCR Signaling in B-ALLBlood Cancer Discovery · 2020
  34. Players in Drug-Resistant Leukemia Stem/Initiating Cells and Immunity in Patients with CML in Context of Oxygen Levels: Would Collecting/Processing Cells in Hypoxia Offer Additional Information? A Next Frontier of InvestigationBlood Cancer Discovery · 2020
  35. Genomic Characterization of HIV-Associated Plasmablastic Lymphoma Identifies Pervasive Mutations in the JAK–STAT PathwayBlood Cancer Discovery · 2020
  36. Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic LeukemiaBlood Cancer Discovery · 2020
  37. Apolipoprotein C2 - CD36 Promotes Leukemia Growth and Presents a Targetable Axis in Acute Myeloid LeukemiaBlood Cancer Discovery · 2020
  38. Cytotoxic Therapy–Induced Effects on Both Hematopoietic and Marrow Stromal Cells Promotes Therapy-Related Myeloid NeoplasmsBlood Cancer Discovery · 2020
  39. Gene Expression Profiling of Mediastinal Gray Zone Lymphoma and Its Relationship to Primary Mediastinal B-cell Lymphoma and Classical Hodgkin LymphomaBlood Cancer Discovery · 2020
  40. Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating FunctionsBlood Cancer Discovery · 2020
  41. Monosomic Loss of MIR15A/MIR16-1 Is a Driver of Multiple Myeloma Proliferation and Disease ProgressionBlood Cancer Discovery · 2020
  42. Mutational Landscape and Patterns of Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic LeukemiaBlood Cancer Discovery · 2020